2Landolfi R,Marchioli R,Kutti J,et al. Efficacy and safety of low- dose aspirin in polycythemia vera[ J ]. N Engl J Med,2004, 350(2) :114.
3Falanga A,Marchetti M,Evangdista V,et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera [ J ]. Blood,2000,96 (13) :4261.
4Jensen MK, de Nully Brown P, Lund BV, et al. Increased circulating platelet - leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count [ J ]. Eur J Haematol,2001,66 (3) : 143.
5Falanga A,Marehetti M,Vignoli A,et al. Leukocyte-platelet interaction in patients with essential thromboeythemia and polyeythemia vera[ J ]. Exp Hematol,2005,33 (5) :523.
6Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis:recommendations from an ad hoe international expertpanel [J]. Blood,2007,110(4) :1092.
7Baxter E J, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [ J ]. Lancet,2005,365 (9464) : 1054.
8James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [ J ]. Nature,2005,434 (7037) : 1144.
9Kralovics R, Passamonti F, Buser AS, et al. A gain - of - function mutation of JAK2 in myeloproliferative disorders [ J ]. N Engl J Med,2005,352(17) :1779.
10Levine RL,Wadleigh M,Cools J,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis[ J]. Cancer Cell,2005,7(4) :387.
